Carl Minniti is an associate in the Litigation practice of Paul Hastings in the firm’s New York office. His practice primarily focuses on complex patent and IP-related litigation matters, with an emphasis on the life science, medical device, and chemical sectors. Mr. Minniti has represented major pharmaceutical companies in cases arising under the Biologics Price Competition & Innovation Act (BPCIA) and the Hatch-Waxman Act.

Mr. Minniti served as a law clerk to Chief Judge Leonard P. Stark of the U.S. District Court for the District of Delaware in 2019–20 before returning to the firm. During law school, Mr. Minniti worked in the New Jersey State Senate on legal and policy debates. He also served as a judicial intern to Judge Kent A. Jordan of the U.S. Court of Appeals for the Third Circuit, as well as Judge Gregory M. Sleet and Magistrate Judge Christopher J. Burke of the U.S. District Court for the District of Delaware.

Mr. Minniti received a joint JD / MBA degree from Rutgers Law School with honors. He earned a master’s degree in Biology and BS degree from Saint Joseph’s University. Mr. Minniti is a member of the New York Bar.


  • Recognized for Best Academic IP Article at Antitrust Writing Awards (2017)—selected by, among others, trade commissioners from the US, Hong Kong, and EU, in-house counsel, and leading academics.
  • Published in Cornell Law Review Online, University of Illinois Law Review, American University Law Review, ABA SciTech Lawyer, Journal of the Patent & Trademark Office Society, and other legal publications.
  • Biosimilar Patent Litigation Bill Would Change BPCIA Strategy, Law360 (July 2019) (with Bruce M. Wexler & Eric W. Dittmann)
  • Federal Circuit Court Latest Guidance On Method-Of-Treatment Claims, Law360 (April 2018) (with Preston K. Ratliff II & Edwin Mok)
  • Three Antitrust Cases Drug Companies Should Watch This Year, Law360 (January 2018) (with Chad J. Peterman)
  • Minniti has advised Congress on proposed legislation involving competition, patent rights, and regulatory schemes in the biologics and biosimilars market.


Rutgers Law School, JD / MBA, 2017

Saint Joseph’s University, MA, 2013

Saint Joseph’s University, BS, 2010


  • Boehringer Ingelheim in BPCIA patent litigation relating to the company’s request to market Cyltezo® (adalimumab-abdm), a biosimilar of Humira® (adalimumab).
  • Merck Sharp & Dohme in Hatch-Waxman patent litigation involving generic challenge to Entereg® (alvimopan), an innovative treatment used for post-operative ileus.

Practice Areas

Intellectual Property

Life Sciences and Healthcare


Patent Litigation





New York Bar


Rutgers Law School, JD / MBA 2017

Saint Joseph's University, M.A. 2013

Saint Joseph's University, B.S. 2010

Nehmen Sie Kontakt mit uns auf

Kontaktiere uns